Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic

Ontario Industry Updates
Written By Viktoriya Shabat

Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced, on November 8, it has received a Peer-Reviewed Medical Research Program (PRMRP) Clinical Trial Award (CTA) grant for US $6.4 million from the U.S. Department of Defense (DOD).

In addition, the company is receiving advisory services and research and development funding of up to $2.8 Million from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

Financial support will enable Vasomune to accelerate clinical development of AV-001 for the Treatment of Patients with Severe COVID-19 Disease and COVID-associated ARDS.

Vasomune in an OBIO® member.

Viktoriya Shabat
Previous

Huron Digital Pathology Invests to Expand Its Manufacturing Capacity as Part of the Province’s Investment to Boost Local Economy in Waterloo Region
Next

Roundtable Discussion with Minister of Economic Development, Job Creation and Trade Victor Fedeli on Supporting a Scaling Commercial Health Science Industry